I'm hoping your swollen lymph nodes are something else and not lymphoma. I would not assume you have it until you are diagnosed as it could be a false alarm.
The FDA posted about
lymphoma cases and tnf-alpha blocking medications initially in 2008
, had a followup in 2009
, and a safety announcement in 2011
. The excerpts below are from the initial 2008 fda posting. The 2011 version has a table by medication, age range, median, etc.
- On June 4th 2008, FDA issued an Early Communication about an ongoing safety review of TNF blockers and the development of lymphoma and other cancers in children and adolescents. The Early Communication was based on approximately 30 reports of cancer in children and adolescents treated with TNF blockers.
The completed FDA analysis identified 48 cases of malignancies in children and adolescents. Of the 48 cases reviewed by FDA, approximately half were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. Other malignancies reported include leukemia, melanoma, and solid organ cancers. Malignancies such as leiomyosarcoma, hepatic malignancies, and renal cell carcinoma, which are rare in children, were also reported. Of the 48 cases of malignancy, there were 11 deaths. The causes of death included hepatosplenic T-cell lymphoma (9 cases) and T-cell lymphoma (1 case). In the remaining case, the patient died from sepsis after achieving remission of the lymphoma.
- FDA reviewed 147 post-marketing reports of leukemia in all patients, including adults, using TNF blockers. Of the 147 cases, acute myeloid leukemia (44 cases), chronic lymphocytic leukemia (31 cases), and chronic myeloid leukemia (23 cases) were the most frequently classified types of leukemia reported. Four pediatric cases of leukemia were reported in the review. Most patients (61%) were also receiving other immunosuppressive therapies. There were a total of 30 deaths reported. In 26 of the 30 deaths, the cause was reported to be leukemia, and the event was associated with the use of TNF blockers. The average time to onset of leukemia was within the first 1 to 2 years of therapy.
The following "Risk of Lymphoma in Inflammatory Bowel Disease
" study goes through the results of some cases, including some meta analyses.